STOCK TITAN

Gracell Biotechnologies Inc - GRCL STOCK NEWS

Welcome to our dedicated news page for Gracell Biotechnologies (Ticker: GRCL), a resource for investors and traders seeking the latest updates and insights on Gracell Biotechnologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gracell Biotechnologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gracell Biotechnologies's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.28%
Tags
conferences
-
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
Gracell Biotechnologies Inc

Nasdaq:GRCL

GRCL Rankings

GRCL Stock Data

989.87M
165.04M
16.39%
63.11%
1.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China
Suzhou

About GRCL

gracell biotechnologies inc. is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. leveraging its pioneering fastcar and truucar technology platforms, gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional car-t therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective car-t therapies for solid tumors.